Apollomics, Inc. (NASDAQ:APLM) Sees Large Growth in Short Interest

Apollomics, Inc. (NASDAQ:APLM) was the target of a large increase in short interest during the month of November. As of November 30th, there was short interest totalling 24,300 shares, an increase of 737.9% from the November 15th total of 2,900 shares. Approximately 3.6% of the shares of the stock are short sold. Based on an average daily volume of 298,400 shares, the short-interest ratio is presently 0.1 days.

Institutional Trading of Apollomics

An institutional investor recently raised its position in Apollomics stock. George Kaiser Family Foundation lifted its stake in shares of Apollomics, Inc. (NASDAQ:APLM) by 2,585.6% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 670,976 shares of the company’s stock after acquiring an additional 645,992 shares during the quarter. Apollomics accounts for about 0.0% of George Kaiser Family Foundation’s portfolio, making the stock its 18th largest position. George Kaiser Family Foundation owned 0.75% of Apollomics worth $141,000 as of its most recent filing with the Securities and Exchange Commission. 19.13% of the stock is owned by hedge funds and other institutional investors.

Apollomics Trading Up 9.1 %

APLM traded up $0.65 during trading hours on Wednesday, reaching $7.81. The company’s stock had a trading volume of 20,016 shares, compared to its average volume of 93,278. Apollomics has a fifty-two week low of $6.50 and a fifty-two week high of $105.00. The business’s 50-day moving average is $12.17 and its 200-day moving average is $15.90.

Apollomics Company Profile

Apollomics, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of oncology therapies to harness the immune system and target specific molecular pathways to eradicate cancer. The company’s products portfolio includes Vebreltinib (APL-101), an oral active, highly selective c-Met inhibitor, which is in Phase 2 clinical trials for treatment of non-small cell lung cancer; APL-102, an oral active, small molecule Multiple Tyrosine Kinase Inhibitor, which is in a in a Phase 1 clinical trial to inhibit various kinases that are aberrantly activated in cancer cells; and APL-122, a tumor inhibitor candidate, targeting ErbB1/2/4 signaling pathwaysthat is in Phase 1 dose escalation clinical trials to treat cancers within the brain.